K.J. Harrison & Partners Inc Raises Holdings in BriaCell Therapeutics Corp. (NASDAQ:BCTX)

K.J. Harrison & Partners Inc grew its position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 22.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 80,715 shares of the company’s stock after purchasing an additional 14,625 shares during the quarter. K.J. Harrison & Partners Inc’s holdings in BriaCell Therapeutics were worth $476,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, K2 Principal Fund L.P. purchased a new position in shares of BriaCell Therapeutics during the 3rd quarter valued at $156,000. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

BriaCell Therapeutics Price Performance

Shares of NASDAQ BCTX traded down $0.07 during trading on Friday, reaching $2.17. 36,051 shares of the stock traded hands, compared to its average volume of 47,456. BriaCell Therapeutics Corp. has a 52-week low of $2.01 and a 52-week high of $7.59. The company has a 50-day moving average of $2.82 and a 200-day moving average of $3.93. The stock has a market capitalization of $34.68 million, a P/E ratio of -1.33 and a beta of 1.02.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.51). Analysts expect that BriaCell Therapeutics Corp. will post -1.39 earnings per share for the current fiscal year.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.